Author:
Belmatoug Nadia,Burlina Alberto,Giraldo Pilar,Hendriksz Chris J.,Kuter David J.,Mengel Eugen,Pastores Gregory M.
Subject
Genetics(clinical),Genetics
Reference40 articles.
1. Actelion (2009) FDA advisory briefing book for miglustat (OGT 918, Zavesca®) in Niemann-Pick type C disease. Retrieved 11th April, 2011, from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM196758.pdf .
2. Actelion (2010) Zavesca® (miglustat capsules) Prescribing Information. Available at: http://www.zavesca.com/pdfs/zavesca_pi.pdf . Accessed 9 June, 2011.
3. Andersson U, Butters TD, Dwek RA et al (2000) N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59:821–829
4. Champion H, Ramaswami U, Imrie J, et al. (2010) Dietary modifications in patients receiving miglustat. J Inherit Metab Dis [Epub ahead of print]. doi: 10.1007/s10545-008-0923-9 .
5. Collins AJ, James PS, Smith MW (1989) Sugar-dependent selective induction of mouse jejunal disaccharidase activities. J Physiol 419:157–167
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献